Methods for treating il-6 mediated inflammation without immunosuppression
OwnerMadhav N. Devalaraja, Michael H. Davidson +1inventors
InventorsMadhav N. Devalaraja, Michael H. Davidson, Rahul Kakkar
Life of this patent
Estimating the term…
Abstract
The disclosure provides methods of treating inflammation without inducing immune suppression. The method comprises administering a therapeutically effective amount of an IL-6 antagonist at a dose sufficient to reduce inflammation without causing immune suppression.
Claims50
A method for treating IL-6-mediated inflammation in a patient, comprising:
- administering an IL-6 antagonist to a patient with IL-6-mediated inflammation at a dose that is sufficient to reduce inflammation without causing immune suppression.
4-11. (canceled)
14-18. (canceled)
21-33. (canceled)
35-41. (canceled)
45-50. (canceled)
52-57. (canceled)
59-141. (canceled)
144-187. (canceled)
(canceled)
192-199. (canceled)
201-207. (canceled)
209-210. (canceled)
212-213. (canceled)
(canceled)
220-223. (canceled)
(canceled)
A method for treating inflammation in a patient with cardiovascular disease, comprising:
- administering an IL-6 antagonist to a patient with cardiovascular disease and CRP level greater than 2 mg/L at a dose that is sufficient to reduce CRP levels to 2 mg/L or less without causing neutropenia.
230-232. (canceled)
A method for treating inflammation in a patient with chronic kidney disease (CKD ), comprising:
- administering an IL-6 antagonist to a patient with CKD and a CRP level greater than 2 mg/L at a dose that is sufficient to reduce CRP levels to 2 mg/L or less without causing neutropenia.
234-236. (canceled)
Dependencies are inferred from the claim text.